Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Average Target Price from Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLPGet Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $56.00.

A number of research analysts recently commented on SLP shares. JMP Securities started coverage on Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating for the company. Oppenheimer increased their price target on Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 13th. Craig Hallum reissued a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a report on Wednesday, July 3rd. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target for the company. Finally, William Blair began coverage on Simulations Plus in a report on Friday, June 28th. They issued an “outperform” rating for the company.

Read Our Latest Report on Simulations Plus

Simulations Plus Price Performance

Shares of NASDAQ SLP opened at $38.60 on Monday. Simulations Plus has a 1-year low of $32.69 and a 1-year high of $52.69. The business has a 50-day moving average of $44.25 and a 200-day moving average of $43.84. The company has a market capitalization of $772.39 million, a price-to-earnings ratio of 80.42 and a beta of 0.72.

Simulations Plus (NASDAQ:SLPGet Free Report) last issued its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. The firm had revenue of $18.54 million during the quarter, compared to the consensus estimate of $17.92 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. Simulations Plus’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.20 earnings per share. Research analysts expect that Simulations Plus will post 0.52 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 5th. Shareholders of record on Monday, July 29th will be paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Monday, July 29th. Simulations Plus’s payout ratio is currently 50.00%.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Daniel L. Weiner sold 750 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $49.32, for a total transaction of $36,990.00. Following the sale, the director now owns 7,009 shares in the company, valued at $345,683.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Daniel L. Weiner sold 750 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the sale, the director now owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel L. Weiner sold 3,250 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the transaction, the director now owns 8,759 shares of the company’s stock, valued at approximately $423,147.29. The disclosure for this sale can be found here. Insiders have sold 44,500 shares of company stock worth $1,945,798 over the last quarter. 20.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Simulations Plus

Several institutional investors have recently modified their holdings of SLP. Vanguard Group Inc. lifted its holdings in Simulations Plus by 0.4% in the third quarter. Vanguard Group Inc. now owns 1,118,878 shares of the technology company’s stock worth $46,657,000 after purchasing an additional 5,009 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in Simulations Plus by 12.5% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,259,176 shares of the technology company’s stock worth $101,098,000 after purchasing an additional 251,299 shares during the period. Mutual of America Capital Management LLC lifted its holdings in Simulations Plus by 12.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 80,884 shares of the technology company’s stock worth $3,620,000 after purchasing an additional 8,998 shares during the period. Cook Wealth Management Group LLC lifted its holdings in Simulations Plus by 12.2% in the fourth quarter. Cook Wealth Management Group LLC now owns 15,624 shares of the technology company’s stock worth $699,000 after purchasing an additional 1,702 shares during the period. Finally, Louisiana State Employees Retirement System acquired a new stake in Simulations Plus in the fourth quarter worth about $358,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

(Get Free Report

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

See Also

Analyst Recommendations for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.